InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development

Share on twitter Share on linkedin SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–InterVenn Biosciences today announced the completion of a $201 million Series C financing. The funding round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors, Highside Capital Management, and backed by existing investors Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures. […]

Loading...